Redcare Pharmacy stock
RDC.DEXETRARedcare Pharmacy N.V., HealthcareISIN NL0012044747
47Score 47 out of 100, Weak
Price and trend
78 / 100
Price history
+8.8% in one yearThe chart shows daily closes over 10 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 20% above it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 37).
The price is 12% below its 52-week high. Largest decline in 10 years: 87% (February 2021 to March 2026).
Chart figures for advanced users
- SMA 50$75.58
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$64.53
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)37
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$34.20
- The lowest closing price of the last twelve months.
- Resistance$87.82
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Redcare Pharmacy N.V. belongs to the Medical (Distribution) industry (Netherlands) and, with a market value of $1.57B, is number 11 of 17 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $3.26B (up 24.1% year on year) and a loss of $41.78M.
- For fiscal 2026, analysts expect on average revenue of $3.83B (up 17.7%) and adjusted earnings per share of −$0.26.
Show more
- MEQIRI Score 47 out of 100 (Weak): rank 421 of 702 in Healthcare, median 53.
- Our model puts fair value at $291.57, with the price 73% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 24.9% a year since 2020, Medical (Distribution) median 9.5%.Growth 70
Weaknesses
- DilutionShare count up 40% since 2020.Capital allocation 19
- Loss-makingLoss of $37.67M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$35.58M over the last 12 months.Fundamentals 17
Its standout strengths are valuation and technical analysis, while fundamentals and profitability hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high price swings
Valuation
Valuation signal
Possible value trapIn our model the price counts as cheap below $194.38 and expensive above $583.15 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 7.5%. At 8.5% the fair value would be $237.91, at 6.5% it would be $371.66.
Possible value trap: looks cheap, but score below 50, weak balance sheet.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 18.6% on the twelve months before. Revenue has grown strongly since 2013, at around 39% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 20%, operating −1%, net −1%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 3 Mar 2027in 110 days
- Last reported
- 29 Oct 2026EPS reported −$0.01 (expected $0.07)below expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 16.3% since 15 Oct 2026.
- Earnings per share
- −$0.26+16.3%
- Revenue
- $3.83B+0.2%
- Earnings per share
- $1.45+1.3%
- Revenue
- $4.3B+0.4%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −4.6%Guidance unchanged after the June raise (growth of 15% to 17%); a significant slowdown of Rx in Germany is already built in.
“Total revenue growth, we moved the range up to 15%-17%, from 13%-15% back in March.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 29 Jul 2026 (fiscal Q2 2026), read by AI.
What happened at Redcare Pharmacy
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 47
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Distribution)
The next larger and next smaller companies by market value
- GalenicaGALE.SW $5.42B59
- AmplifonAMP.MI $3.47B47
- Asker Healthcare GroupASKER.ST $2.8B61
- Sopharma ADSPH.WA $1.88B57
- UnipharUPR.IR $1.25B57
- Akso Health GroupAHG $1.15B35
- DocMorrisDOCM.SW $1.15B39
- ArjoARJO-B.ST $924.06M59
ETFs that hold Redcare Pharmacy
Held by 10 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Amundi SDAX UCITS ETF DistC005 | 3.05% | 0.70% | €158.8M |
| Amundi MSCI EMU Small Cap ESG Broad Transition UCITS ETF DISTLGWU | 0.42% | 0.40% | €580.62M |
| iShares MSCI EMU Small Cap UCITS ETFSXRJ | 0.22% | 0.58% | €838.19M |
Show 5 more
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.17% | 0.23% | €321.86M |
| Vanguard Germany All Cap UCITS ETF (EUR) DistributingVGER | 0.07% | 0.07% | €255.26M |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.06% | 0.10% | €395.74M |
| iShares Digitalisation UCITS ETF2B79 | 0.05% | 0.40% | €736.08M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.01% | 0.35% | €8.27B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Nov 2017)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.